PolicyWinds
Topic and direction labels are AI-assisted, and each one quotes the bill text it is based on. How labels work
Federal · 119th Congress

S4066 Safeguarding Women from Chemical Abortion Act

Direction

Abortion medication abortionAI label

Restricts abortion access model confidence 95%

Deems FDA approval of mifepristone for terminating intrauterine pregnancy withdrawn and treats its distribution as a violation, so less medication abortion access.

Approval of an application submitted under subsection (b) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for the drug mifepristone (marketed as Mifeprex, and also known as RU-486) with an indication for the termination of intrauterine pregnancy, and of any application submitted under subsection (j) of such section for a drug with the same indication and for which mifepristone is the reference drug, is deemed to have been withdrawn under subsection (e) of such section.

✓ Quote verified word for word in the bill text

Abortion provider clinic regulationAI label

Restricts abortion access model confidence 80%

Imposes federal tort liability on manufacturers of mifepristone for harms from its use in chemical abortion, increasing legal exposure for entities involved in medication abortion.

A covered entity shall be liable in accordance with this section to any individual who suffers bodily injury or harm to mental health (including any physical, psychological, emotional, or physiological harm) that is attributable, in whole or in part, to the individual's use of a covered medication manufactured by a covered entity.

✓ Quote verified word for word in the bill text

  1. Introduced (completed)
  2. Committee
  3. Passed one chamber
  4. Passed both
  5. President
  6. Law

Stage: Committee · step 2 of 6

Last action
2026-03-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Filed
2026-03-11
Committee
Health, Education, Labor, and Pensions Committee
Sponsor
Josh Hawley R + 7 cosponsors (7 R)

Why the model tagged it this way: The bill substantively addresses abortion by withdrawing FDA approval for mifepristone (the primary medication used for chemical abortion) and creating manufacturer liability for harms from its use, both of which restrict access to medication abortion and related services. No provisions address firearms, transgender issues, or immigration enforcement.

Related bills

Sponsors

Text versions

History (2 actions)
DateChamberAction
2026-03-11LibraIntroduced in Senate
2026-03-11SenatRead twice and referred to the Committee on Health, Education, Labor, and Pensions.